Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results

HOLZEROVÁ, Milena, Edgar FABER, Jitka VESELOVSKÁ, Helena URBÁNKOVÁ, Jana BALCÁRKOVÁ, Šárka ROŽMANOVÁ, Jaroslava VOGLOVÁ, Jan MUŽÍK, Karel CHROUST, Karel INDRÁK a Marie JAROŠOVÁ. Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results. Online. Cancer Genetics and Cytogenetics. 2009, roč. 191, č. 1, s. 1-9. ISSN 0165-4608. [citováno 2024-04-24]

Základní údaje

• Originální název: Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results
• Název česky: Účinnost imatinib mesylatu u 72 Ph+ CML pacientů s přídavnými a bez přídavných chromozomálních změn: výsledky jednoho centra
• Autoři: HOLZEROVÁ, Milena (203 Česká republika, garant), Edgar FABER (703 Slovensko), Jitka VESELOVSKÁ (203 Česká republika), Helena URBÁNKOVÁ (203 Česká republika), Jana BALCÁRKOVÁ (203 Česká republika), Šárka ROŽMANOVÁ (203 Česká republika), Jaroslava VOGLOVÁ (203 Česká republika), Jan MUŽÍK (203 Česká republika), Karel CHROUST (203 Česká republika), Karel INDRÁK (203 Česká republika) a Marie JAROŠOVÁ (203 Česká republika)
• Vydání: Cancer Genetics and Cytogenetics, 2009, 0165-4608.

Další údaje

• Originální jazyk: angličtina
• Typ výsledku: Článek v odborném periodiku
• Obor: 30200 3.2 Clinical medicine
• Stát vydavatele: Velká Británie a Severní Irsko
• Utajení: není předmětem státního či obchodního tajemství
• Impakt faktor: Impact factor: 1.537
• Kód RIV: RIV/00216224:14110/09:00036075
• Organizační jednotka: Lékařská fakulta
• UT WoS: 000266023700001
• Klíčová slova anglicky: CML; imatinib; chromosomal changes
• Štítky: chromosomal changes, CML, imatinib

Anotace

Reported here are 72 previously treated Philadelphia chromosome-positive (Ph+) CML patients on imatinib (IM) therapy, with a focus on patients with additional chromosomal aberrations (CAs). At the start of IM treatment, 49 patients exhibited only the Ph chromosome (68%) and 23 patients (32%) had one or more additional CAs. There was no statistically significant difference in the overall survival of patients with additional CAs and patients with Ph as the sole abnormality. Patients in accelerated phase had significantly worse overall survival on IM, regardless of additional CAs. The present results confirm that the majority of previously treated Ph+ CML patients benefit from starting IM therapy, including patients with defined additional changes. In contrast, patients with complex karyotypes have poor prognosis, even with IM.

Anotace česky

Reported here are 72 previously treated Philadelphia chromosome-positive (Ph+) CML patients on imatinib (IM) therapy, with a focus on patients with additional chromosomal aberrations (CAs). At the start of IM treatment, 49 patients exhibited only the Ph chromosome (68%) and 23 patients (32%) had one or more additional CAs. There was no statistically significant difference in the overall survival of patients with additional CAs and patients with Ph as the sole abnormality. Patients in accelerated phase had significantly worse overall survival on IM, regardless of additional CAs. The present results confirm that the majority of previously treated Ph+ CML patients benefit from starting IM therapy, including patients with defined additional changes. In contrast, patients with complex karyotypes have poor prognosis, even with IM.